Breaking News, Collaborations & Alliances

Amgen, Adaptive Biotech Enter COVID-19 Antibody Alliance

Aims to accelerate the development of a potential antibody against COVID-19 as fast as possible

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen and Adaptive Biotechnologies have entered a collaboration to discover and develop fully human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19. The exclusive collaboration brings together Adaptive’s immune medicine platform for the identification of virus-neutralizing antibodies with Amgen’s expertise in immunology and novel antibody therapy development. Neutralizing antibodies defend healthy cells by interfering with the biological funct...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters